Microarray Analysis in a Cell Death Resistant Glioma Cell Line to Identify Signaling Pathways and Novel Genes Controlling Resistance and Malignancy

Glioblastoma multiforme (GBM) is a lethal type of cancer mainly resistant to radio- and chemotherapy. Since the tumor suppressor p53 functions as a transcription factor regulating the expression of genes involved in growth inhibition, DNA repair and apoptosis, we previously assessed whether specific differences in the modulation of gene expression are responsible for the anti-tumor properties of a dominant positive p53, chimeric tumor suppressor (CTS)-1. CTS-1 is based on the sequence of p53 and designed to resist various mechanisms of inactivation which limit the activity of p53. To identify CTS-1-regulated cell death-inducing genes, we generated a CTS-1-resistant glioma cell line (229R). We used Affymetrix whole-genome microarray expression analysis to analyze alterations in gene expression and identified a variety of CTS-1 regulated genes involved in cancer-linked processes. 313 genes were differentially expressed in Adeno-CTS-1 (Ad-CTS-1)-infected and 700 genes in uninfected 229R cells compared to matching parental cells. Ingenuity Pathway Analysis (IPA) determined a variety of differentially expressed genes in Ad-CTS-1-infected cells that were members of the intracellular networks with central tumor-involved players such as nuclear factor kappa B (NF-κB), protein kinase B (PKB/AKT) or transforming growth factor beta (TGF-β). Differentially regulated genes include secreted factors as well as intracellular proteins and transcription factors regulating not only cell death, but also processes such as tumor cell motility and immunity. This work gives an overview of the pathways differentially regulated in the resistant versus parental glioma cells and might be helpful to identify candidate genes which could serve as targets to develop novel glioma specific therapy strategies.

[1]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[2]  U. Naumann,et al.  Gene expression profile in a glioma cell line resistant to cell death induced by the chimeric tumor suppressor-1 (CTS-1), a dominant-positive variant of p53--the role of NFkappaB. , 2010, Carcinogenesis.

[3]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[4]  G. Fuller,et al.  Overexpression of IGFBP5, but not IGFBP3, Correlates with the Histologic Grade of Human Diffuse Glioma: A Tissue Microarray and Immunohistochemical Study , 2006, Technology in cancer research & treatment.

[5]  Tanja Woyke,et al.  Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. , 2005, Neoplasia.

[6]  M. Weller,et al.  PCTAIRE3: a putative mediator of growth arrest and death induced by CTS-1, a dominant-positive p53-derived synthetic tumor suppressor, in human malignant glioma cells , 2006, Cancer Gene Therapy.

[7]  R. Jenkins,et al.  Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. , 2000, Frontiers in bioscience : a journal and virtual library.

[8]  J. Pichler,et al.  Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. , 2007, Oligonucleotides.

[9]  R. Krüger,et al.  Microarray expression analysis reveals genetic pathways implicated in C621 synphilin-1-mediated toxicity , 2008, Journal of Neural Transmission.

[10]  P. Black,et al.  In vitro and In vivo Activity of the Nuclear Factor-κB Inhibitor Sulfasalazine in Human Glioblastomas , 2004, Clinical Cancer Research.

[11]  P. Kleihues,et al.  The p53 gene and its role in human brain tumors , 1995, Glia.

[12]  Yan Zhou,et al.  The chemokine GRO-α (CXCL1) confers increased tumorigenicity to glioma cells , 2005 .

[13]  Amanda Y. Chan,et al.  Tumorigenesis and Neoplastic Progression The Guanine Nucleotide Exchange Factors Trio , Ect 2 , and Vav 3 Mediate the Invasive Behavior of Glioblastoma , 2010 .

[14]  S. Kügler,et al.  Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. , 2001, Cancer research.

[15]  O. Sarig,et al.  Insulin-like growth factor-binding protein 7 regulates keratinocyte proliferation, differentiation and apoptosis. , 2010, The Journal of investigative dermatology.

[16]  Yusuke Nakamura,et al.  p53RDL1 regulates p53-dependent apoptosis , 2003, Nature Cell Biology.

[17]  M. Weller,et al.  A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis , 2008, Cell Death and Differentiation.

[18]  Michael Weller,et al.  TP53 promoter methylation in human gliomas , 2005, Acta Neuropathologica.

[19]  S. Nelson,et al.  DNA-microarray analysis of brain cancer: molecular classification for therapy , 2004, Nature Reviews Neuroscience.

[20]  Susan M. Chang,et al.  Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. , 2010, Neuro-oncology.

[21]  T. Veres,et al.  Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies , 2010, British Journal of Cancer.

[22]  D. Tong,et al.  HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. , 2005, Oncology reports.

[23]  Y. Durocher,et al.  Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-β signaling , 2008, Oncogene.

[24]  D. Hayes,et al.  Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy , 2010, British Journal of Cancer.

[25]  Yan Zhou,et al.  The chemokine GRO-alpha (CXCL1) confers increased tumorigenicity to glioma cells. , 2005, Carcinogenesis.

[26]  D. Stanimirovic,et al.  Molecular markers of extracellular matrix remodeling in glioblastoma vessels: Microarray study of laser‐captured glioblastoma vessels , 2007, Glia.

[27]  R. Dalla‐Favera,et al.  Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.

[28]  K. Schulze-Osthoff,et al.  A Novel Member of the IκB Family, Human IκB-ζ, Inhibits Transactivation of p65 and Its DNA Binding* , 2006, Journal of Biological Chemistry.

[29]  L. Bracco,et al.  CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. , 1998, The Journal of clinical investigation.

[30]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[31]  J. Inoue,et al.  TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3 and Activates NF-κB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase1 , 2000, The Journal of Immunology.

[32]  N. Fusenig,et al.  Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. , 1999, The American journal of pathology.

[33]  K. Schulze-Osthoff,et al.  A novel member of the IkappaB family, human IkappaB-zeta, inhibits transactivation of p65 and its DNA binding. , 2006, The Journal of biological chemistry.

[34]  J. Pichler,et al.  Inhibition of TGF-β2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies , 2007 .

[35]  E. Bowman,et al.  Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. , 2004, Human pathology.

[36]  Marcel Leist,et al.  Cathepsin B Acts as a Dominant Execution Protease in Tumor Cell Apoptosis Induced by Tumor Necrosis Factor , 2001, The Journal of cell biology.

[37]  T. Mikkelsen,et al.  Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration. , 2008, Neoplasia.

[38]  José Luis de la Pompa,et al.  Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.

[39]  G. Fuller,et al.  Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas , 2004, Laboratory Investigation.

[40]  M. Weller,et al.  Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. , 2006, Current pharmaceutical design.

[41]  Y. Loh,et al.  Carboxypeptidase E: Elevated Expression Correlated with Tumor Growth and Metastasis in Pheochromocytomas and Other Cancers , 2010, Cellular and Molecular Neurobiology.

[42]  A. Look,et al.  Slug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing puma , 2005, Cell.

[43]  M. Weller,et al.  CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death , 2003, Oncogene.